As of Nov 17
| 0.00 / 0.00%|
The 2 analysts offering 12-month price forecasts for Novelion Therapeutics Inc have a median target of 9.25, with a high estimate of 10.50 and a low estimate of 8.00. The median estimate represents a +75.86% increase from the last price of 5.26.
The current consensus among 2 polled investment analysts is to Outperform stock in Novelion Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.